David Elliot Lazar's most recent trade in Kala Pharmaceuticals Inc was a trade of 900,000 Series AA Convertible Preferred Stock done . Disclosure was reported to the exchange on Nov. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharma Inc | David Elliot Lazar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Nov 2025 | 900,000 | 900,000 | - | - | Series AA Convertible Preferred Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 12.36 per share. | 30 Jul 2025 | 6,750 | 155,838 (0%) | 0% | 12.4 | 83,430 | Common Stock |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.03 per share. | 26 Feb 2025 | 194,628,820 | 0 (0%) | 1131% | 0.0 | 5,507,996 | Common Stock |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 191,978,820 | 194,628,820 (999.99%) | 1116% | - | Common Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,650,000 | 2,650,000 (15%) | 15% | - | Common Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,745,262 | 354,738 | - | - | Series D Convertible Preferred Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,000,000 | 0 | - | - | Series C Convertible Preferred Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 2,100,000 | 2,100,000 | - | - | Series D Convertible Preferred Stock |